- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00985582
Antiviral Therapy for Influenza A H1N1 (SEA032)
Antiviral Treatment in Adults and Children With Novel Influenza A (H1N1) Respiratory Tract Infection - a Clinical, Virological and Pharmacokinetic Study.
The aims of this study are to characterise the clinical efficacy and virological clearance dynamics of orally administered oseltamivir in patients with influenza caused by novel influenza A(H1N1). This research will also contribute to enhancing research capacity in affected countries.
The objectives are to assess the:
- viral replication levels over time in affected patients
- antiviral efficacy of oral oseltamivir
- patterns and compartments of viral shedding, tissue distribution
- innate inflammatory response and relation to viral replication
- kinetics of antibody response
- antiviral sensitivity of influenza viruses at baseline and during oseltamivir treatment using in vitro and molecular methods
- pharmacokinetic characteristics of oseltamivir and oseltamivir carboxylate
- all cause in hospital mortality
- clinical and radiological features, disease course and outcome
- length of stay in hospital
- risk factors associated with development of severe disease and death
Studieoversikt
Status
Forhold
Detaljert beskrivelse
Any patient over 1 year of age who presents to a participating institution with confirmed influenza A and who meets the study inclusion/exclusion criteria may be approached for informed consent. Choice of antiviral is up to the study physician. Children aged 1-6 years and asthmatics should receive oseltamivir. The weight- and age-adjusted dosage used will be that approved for treatment of uncomplicated seasonal influenza, and doses will be administered twice daily for 5 days for patients with normal renal function. All patients who are clinical and/or virologic failures at day 5 will be treated for an additional 5 days of antivirals. After coming off antiviral therapy patients can be discharged at day 10 if deemed ready by study physicians and they are virologically negative.
During the course of treatment study evaluations will be performed to determine primary efficacy end points including viral clearance on Day 5 on all collected nasopharyngeal samples, assessed by RT PCR for novel H1N1 influenza AND no clinical features of clinical failure. Evaluations will also be performed to determine secondary viral, serological, clinical efficacy, safety and pharmacokinetic endpoints.
Patients will be followed up for up to 6 months after discharge for a clinical assessment, pulmonary function and outcome of pregnancy.
The protocol will be reviewed after 6 months from starting or after 100 patients with Influenza A are recruited.
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
-
Hanoi, Vietnam
- National Institute for Infectious and Tropical Diseases (NIITD), Viet Nam
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
This is a single arm clinical and virological study assessing the use of oral oseltamivir or other agents in the treatment of patients with novel influenza A(H1N1) infection.
Any patient over 1 year of age with confirmed novel influenza A(H1N1) in whom appropriate informed consent to collect data and samples is obtained. The protocol will be reviewed after 6 months from starting or after 100 patients with new influenza A(H1N1) are recruited.
Beskrivelse
Inclusion Criteria:
- Adults, including pregnant and breast feeding women, and Children aged ≥ 12 months when first seen with an acute febrile respiratory tract illness (ARI) of any severity and influenza A, virologically proven on a respiratory specimen according to hospital procedure, which is suspected to be novel influenza A(H1N1)
- A positive influenza A H1 swine screening reverse transcriptase polymerase chain reaction (RT PCR) or conventional PCR assay on one respiratory specimen : NPA, NP swab, nasal wash, nasal swab and throat swab
- Underlying illnesses including HIV
- Prescribed oseltamivir prior to presentation
Exclusion Criteria:
- Lack of informed consent
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: Bare etui
- Tidsperspektiver: Potensielle
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Viral clearance on Day 5 on all collected nasopharyngeal samples, assessed by RT PCR for new influenza A(H1N1)
Tidsramme: 12 months
|
12 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Viral clearance on Day 1, 2, 3, 4, 5 (H1N1) on nose and throat swab, assessed by RT PCR.
Tidsramme: 12 months
|
12 months
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Jeremy Farrar, MD, Oxford University Clinical Research Unit Ho Chi Minh City Vietnam
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Lackenby A, Thompson CI, Democratis J. The potential impact of neuraminidase inhibitor resistant influenza. Curr Opin Infect Dis. 2008 Dec;21(6):626-38. doi: 10.1097/QCO.0b013e3283199797.
- Ferraris O, Lina B. Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. J Clin Virol. 2008 Jan;41(1):13-9. doi: 10.1016/j.jcv.2007.10.020. Epub 2007 Dec 11.
- Shiraishi K, Mitamura K, Sakai-Tagawa Y, Goto H, Sugaya N, Kawaoka Y. High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza. J Infect Dis. 2003 Jul 1;188(1):57-61. doi: 10.1086/375799. Epub 2003 Jun 23.
- Hurt AC, Ho HT, Barr I. Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors. Expert Rev Anti Infect Ther. 2006 Oct;4(5):795-805. doi: 10.1586/14787210.4.5.795.
- Dutkowski R, Thakrar B, Froehlich E, Suter P, Oo C, Ward P. Safety and pharmacology of oseltamivir in clinical use. Drug Saf. 2003;26(11):787-801. doi: 10.2165/00002018-200326110-00004.
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- SEA032
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Influensa A-virusinfeksjon
-
Centre for Infectious Disease Research in ZambiaUniversity of OxfordFullførtHepatitt B-virus | Health Care Associated InfectionZambia
-
National Institute of Allergy and Infectious Diseases...FullførtInfluensa A-virus, H5N1-subtype | Influensa A-virus | Influensavirus A | Orthomyxoviridae | H5N1 virusForente stater
-
National Institute of Allergy and Infectious Diseases...FullførtInfluensa A-virus, H5N1-subtype | Influensa A-virus | Influensavirus A | H5N1 virus | OrthomyxovirdaeForente stater
-
Boryung Biopharma Co., Ltd.Har ikke rekruttert ennåHepatitt A-virus | Hep AKorea, Republikken, Thailand
-
Boryung Pharmaceutical Co., LtdFullførtHepatitt A-vaksineKorea, Republikken
-
Merck Sharp & Dohme LLCFullførtHepatitt A-virusinfeksjon
-
Boryung Pharmaceutical Co., LtdFullførtHepatitt A-vaksineKorea, Republikken
-
GlaxoSmithKlineFullført
-
GlaxoSmithKlineFullførtHepatitt | Akutt hepatitt APanama
-
Chiang Mai UniversityFaculty of Medicine, Chiang Mai UniversityHar ikke rekruttert ennåHepatitt A-virus | Vaksine-forebyggende sykdommer | Hep A | HAV